Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM) J2556

The Brain Cancer Program, in partnership with the Center for Music and Medicine at Johns Hopkins, will study whether music therapy is feasible in newly diagnosed GBM patients undergoing standard care.

Virtually via Zoom, all participants will meet with Music Therapists to create playlists and learn how to complete surveys measuring quality of life.

Participants will be randomly assigned, half to each arm. Arm A will interact with Music Therapists and listen to music twice a week, then independently fill out quality of life questionnaires.

Arm B will listen to music independently twice a week, then independently fill out quality of life questionnaires.

Inclusion Criteria:

• Glioblastoma (Newly Diagnosed)
• Cognitive capacity to respond to surveys
• Access to computer and web access
• Ability to attend virtual music therapy sessions
• Audibly process music
• Proficient in English

Exclusion Criteria:

• Not planning to undergo standard of care radiation therapy and concurrent and adjuvant temozolomide.
• A life expectancy of less than 6 months.
• Concurrent use of any other standard or investigational agents (excepting tumor treating fields).
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit adherence with study requirements.